文献速递膀胱癌与上尿路尿路上皮癌

术前血浆尿激酶纤溶酶原激活物蛋白对根治性膀胱切除术后疾病结局的预后影响

Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy.
PubMed 文献 · J Urol · 2021-06-28

该研究在1036例接受根治性膀胱切除术的尿路上皮癌患者中,验证术前血浆uPA、SuPAR和PAI-1水平与肿瘤学结局的关联。结果显示三种标志物升高与不良病理特征相关,且uPA和SuPAR独立关联无复发生存和癌症特异性生存,加入标准模型可提升预测判别力。

要点

  • 术前血浆uPA、SuPAR和PAI-1升高与不良病理特征显著相关。
  • uPA和SuPAR独立关联无复发生存和癌症特异性生存。
  • 标志物加入标准模型可改善淋巴结转移和≥pT3疾病的预测判别力。

核心结论

  • 术前血浆uPA、SuPAR和PAI-1升高与根治性膀胱切除术后侵袭性疾病特征和更差生存结局相关。

研究设计与样本

  • 回顾性队列研究,连续收集1036例接受根治性膀胱切除术的尿路上皮癌患者的术前血样。

主要发现

  • 术前血浆uPA、SuPAR和PAI-1水平在具有不良病理特征的患者中显著升高。
  • 三种标志物较高水平均独立关联淋巴结转移风险增加;uPA还独立关联≥pT3疾病。
  • 术前uPA和SuPAR独立关联无复发生存和癌症特异性生存。
  • 将标志物加入标准治疗前和治疗后模型,以预后显著幅度改善对淋巴结转移、≥pT3疾病、无复发生存和癌症特异性生存的预测判别力。

临床怎么用

  • 这些标志物可能有助于识别可能从强化/多模式治疗中获益的患者。
  • 标志物可提升预测/预后模型的判别力,从而细化个性化临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We sought to validate the association of plasma levels of urokinase-type plasminogen activator (uPA), its soluble receptor (SuPAR) and its inhibitor (PAI-one) with oncologic outcomes in a large cohort of patients treated with radical cystectomy (RC) for urothelial carcinoma of the bladder (UCB). MATERIALS AND METHODS: We collected preoperative blood samples from 1,036 consecutive patients treated with RC for UCB. Plasma specimens were assessed for levels of uPA, SuPAR and PAI-one. Retrospective logistic and Cox regression analyses were performed to assess their correlation with clinical outcomes. The additional clinical net benefit provided by the biomarkers was evaluated using decision curve analysis. RESULTS: Preoperative plasma uPA, SuPAR and PAI-one levels were significantly elevated in patients harboring adverse pathological features. Higher levels of all biomarkers were independently associated with an increased risk of lymph node metastasis; uPA levels were also independently associated with ≥pT3 disease. Preoperative uPA and SuPAR were independently associated with recurrence-free and cancer-specific survival. The addition of these biomarkers to standard pre-treatment and post-treatment models improved the discriminatory power for prediction of lymph node metastasis, ≥pT3 disease, and recurrence-free and cancer-specific survival by a prognostically significant margin. CONCLUSIONS: We confirmed that elevated preoperative plasma levels of uPA, SuPAR and PAI-one are associated with features of aggressive disease and worse survival outcomes in patients treated with RC for UCB. These biomarkers hold potential in identifying patients who are likely to benefit from intensified/multimodal therapy. They also demonstrated the ability to improve the discriminatory power of predictive/prognostic models, thus refining personalized clinical decision-making.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Schuettfort VM, Pradere B, D'Andrea D, et al. Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy. J Urol. 2021. PMID: 34181469. doi:10.1097/JU.0000000000001936

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。